story of the week
Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet 2024 Oct 05;404(10460)1321-1332, D Lorusso, Y Xiang, K Hasegawa, G Scambia, M Leiva, P Ramos-Elias, A Acevedo, J Cvek, L Randall, AJ Pereira de Santana Gomes, F Contreras Mejía, L Helpman, H Akıllı, JY Lee, V Saevets, F Zagouri, L Gilbert, J Sehouli, E Tharavichitkul, K Lindemann, N Colombo, CL Chang, M Bednarikova, H Zhu, A Oaknin, M Christiaens, E Petru, T Usami, P Liu, K Yamada, S Toker, SM Keefe, S Pignata, LR DuskaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.